Janux Therapeutics Statistics
Total Valuation
JANX has a market cap or net worth of $885.49 million. The enterprise value is -$49.32 million.
Important Dates
The last earnings date was Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
JANX has 60.98 million shares outstanding. The number of shares has increased by 9.22% in one year.
| Current Share Class | 60.98M |
| Shares Outstanding | 60.98M |
| Shares Change (YoY) | +9.22% |
| Shares Change (QoQ) | +0.84% |
| Owned by Insiders (%) | 6.52% |
| Owned by Institutions (%) | 73.10% |
| Float | 39.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 64.48 |
| Forward PS | n/a |
| PB Ratio | 0.94 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.01, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.01 |
| Quick Ratio | 16.95 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -11.72% and return on invested capital (ROIC) is -9.82%.
| Return on Equity (ROE) | -11.72% |
| Return on Assets (ROA) | -9.44% |
| Return on Invested Capital (ROIC) | -9.82% |
| Return on Capital Employed (ROCE) | -16.20% |
| Weighted Average Cost of Capital (WACC) | 17.97% |
| Revenue Per Employee | $127,157 |
| Profits Per Employee | -$1.06M |
| Employee Count | 108 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.38% in the last 52 weeks. The beta is 2.57, so JANX's price volatility has been higher than the market average.
| Beta (5Y) | 2.57 |
| 52-Week Price Change | -41.38% |
| 50-Day Moving Average | 14.45 |
| 200-Day Moving Average | 18.94 |
| Relative Strength Index (RSI) | 51.55 |
| Average Volume (20 Days) | 975,485 |
Short Selling Information
The latest short interest is 7.93 million, so 13.01% of the outstanding shares have been sold short.
| Short Interest | 7.93M |
| Short Previous Month | 7.44M |
| Short % of Shares Out | 13.01% |
| Short % of Float | 20.24% |
| Short Ratio (days to cover) | 7.94 |
Income Statement
In the last 12 months, JANX had revenue of $13.73 million and -$114.48 million in losses. Loss per share was -$1.84.
| Revenue | 13.73M |
| Gross Profit | -113.92M |
| Operating Income | -156.98M |
| Pretax Income | -114.48M |
| Net Income | -114.48M |
| EBITDA | -155.00M |
| EBIT | -156.98M |
| Loss Per Share | -$1.84 |
Full Income StatementBalance Sheet
The company has $956.39 million in cash and $21.57 million in debt, with a net cash position of $934.82 million or $15.33 per share.
| Cash & Cash Equivalents | 956.39M |
| Total Debt | 21.57M |
| Net Cash | 934.82M |
| Net Cash Per Share | $15.33 |
| Equity (Book Value) | 941.54M |
| Book Value Per Share | 15.47 |
| Working Capital | 943.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$77.55 million and capital expenditures -$945,000, giving a free cash flow of -$78.49 million.
| Operating Cash Flow | -77.55M |
| Capital Expenditures | -945,000 |
| Depreciation & Amortization | 1.98M |
| Net Borrowing | n/a |
| Free Cash Flow | -78.49M |
| FCF Per Share | -$1.29 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,143.11% |
| Pretax Margin | -833.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
JANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.22% |
| Shareholder Yield | -9.22% |
| Earnings Yield | -12.93% |
| FCF Yield | -8.86% |
Analyst Forecast
The average price target for JANX is $40.56, which is 179.34% higher than the current price. The consensus rating is "Buy".
| Price Target | $40.56 |
| Price Target Difference | 179.34% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 85.05% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
JANX has an Altman Z-Score of 9.22 and a Piotroski F-Score of 2.
| Altman Z-Score | 9.22 |
| Piotroski F-Score | 2 |
